Document is current

Article History

Received: 2 October 2020

Accepted: 24 October 2020

First Online: 18 November 2020

Compliance with ethical standards

:

: The authors would like to disclose the following: Dolores Isla: Personal financial interests: Consulation Honoraria: AbbVie, Astra-Zeneca, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, MSD, Pierre Fabre, Pfizer, Takeda. Speaker Honoraria: Astra-Zeneca, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, MSD, Pierre Fabre,Pfizer. Institutional financial interests: Clinical Trials: AbbVie, Astra-Zeneca, Boehringer Ingelheim, BMS, F. Hoffmann-La Roche, Janssen, MSD, Novartis, Research Grant: BMS. Javier de Castro: Educational grants: Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Roche. Scientific consulting: Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Pfizer, Roche, Takeda. Rosario García-Campelo: Consulting, advisory role or speaker’s bureau: Boehringer Ingelheim, BMS, Astra-Zeneca, Roche, MSD, Sanofi, Takeda, Pfizer. Margarita Majem: Grants: BMS. Personal fees: BMS, MSD, Boehringer Ingelheim, Astra-Zeneca, Roche, Kyowa Kyrin, Pierre Fabre. Non-financial support: MSD, Boehringer Ingelheim, Astra-Zeneca, Roche. Others: Astra-Zeneca, Roche. David Vicente: Honoraria: Astra-Zeneca, Merck, BMS, Roche, MSD, Pfizer. Consulting or advisory role: Astra-Zeneca, Merck, BMS, Roche, MSD, Pfizer. Expert testimony: MSD. Travel, accomodations, expenses: Astra-Zeneca. Oscar Juan-Vidal: Honoraria or Advisory role: Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genetech, Astra-Zeneca, Pfizer, Eli Lilly, Abbvie, Takeda. Travel, accomodations, expenses: Boehringer Ingelheim, Merck Sharp & Dohme, Roche/Genetech.

: This study consisted of a survey of expert opinions and no patient data were collected, so no specific independent ethical or research review or approval was necessary.

: For this type of study formal consent is not required.